Previous Article | Next Article ![]()
Journal of Clinical Microbiology, March 1998, p. 684-689, Vol. 36, No. 3
Servicio de Microbiologia,
Received 5 August 1997/Returned for modification 10 October
1997/Accepted 2 December 1997
We evaluated the initial version of the Amplified Mycobacterium
Tuberculosis Direct Test (Gen-Probe) (AMTDT 1) and the new version of
AMTDT (AMTDT 2) for the detection of Mycobacterium tuberculosis directly from respiratory and nonrespiratory samples and compared the results with those of culture and staining methods. The assays were applied to 410 respiratory and 272 nonrespiratory samples collected from 515 patients. The combination of the
culture results and clinical diagnosis was considered to be the "gold standard." Ninety-five respiratory specimens were collected from 67 patients with a diagnosis of pulmonary tuberculosis (TB) and 68 nonrespiratory specimens were collected from 61 patients with a
diagnosis of extrapulmonary TB. With respiratory specimens, the
sensitivity, specificity, and positive and negative predictive values
were 83, 100, 100, and 96%, respectively, for AMTDT 1 and 94.7, 100, 100, and 98.4%, respectively, for AMTDT 2. With nonrespiratory specimens, the sensitivity, specificity, and positive and negative predictive values were 83, 100, 100, and 94%, respectively, for AMTDT
1 and 86.8, 100, 100, and 98.4%, respectively, for AMTDT 2. The
overall results of AMTDT 1 and AMTDT 2 were concordant for 97% (661 of
682) of the samples. Statistically significant differences in
sensitivities were found between AMTDT 1 and AMTDT 2 with respiratory
specimens. It was concluded that although both nucleic acid
amplification methods are rapid, sensitive, and specific for the
detection of M. tuberculosis complex in all types of
clinical samples, AMTDT 2 appeared to be more sensitive than AMTDT 1 when applied to smear-negative specimens. In contrast AMTDT 2 is more susceptible than AMTDT 1 to inhibitory substances in the amplification reaction. The turnaround time of AMTDT 2 is shorter (3.5 h) than that
for AMTDT 1 (5 h).
For the detection of
Mycobacterium tuberculosis, microscopic examination of
acid-fast-stained smears and culture are still the methods of choice in
most diagnostic microbiology laboratories. However, both of these
methods have drawbacks. Direct staining for acid-fast bacilli takes
less than an hour but lacks sensitivity (6). Moreover,
a positive result by this test does not discriminate between the
Mycobacterium species. Culture for M. tuberculosis is sensitive and specific but may require 6 to 10 weeks of incubation. The recently developed nucleic acid amplification
methods may provide us with very sensitive, specific, and rapid tests
for the detection of M. tuberculosis, thus combining the
advantages of both of the classical methods.
Since the introduction of nucleic acid amplification assays into
diagnostic mycobacteriology, many publications have confirmed the
sensitivity and specificity of in-house and commercial assays (2, 7, 10, 23, 24, 26, 27, 30, 31). The Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test (AMTDT) uses transcription-mediated amplification and hybridization procedures to
qualitatively detect M. tuberculosis complex rRNA. This
commercially available test has been reported to be a reasonably
reliable tool for the diagnosis of pulmonary and extrapulmonary
tuberculosis (2, 18, 25, 31). The sensitivity of AMTDT
varied from 65 to 97% in different studies, whereas the specificity
was always high (2, 3, 18, 21, 26). A low bacterial load was found to affect the sensitivity of AMTDT more than that of culture (18, 21, 31), thus limiting the usefulness of AMTDT for the
screening of smear-negative specimens (3). In this initial version of AMTDT (AMTDT 1), 50 µl of the pretreated specimen is used
for amplification and detection reaction. Recently, Gen-Probe Inc. has
developed the second version of AMTDT (AMTDT 2), which has an enhanced
protocol. This new version incorporates three main changes: (i) an
increase in the initial amount of pretreated specimen from 45 to 450 µl, (ii) a reduction in the incubation time of the amplification
reaction (60 to 30 min), and (iii) the elimination of the termination
reaction.
The purpose of the present study was to compare the initial and new
versions of Gen-Probe AMTDTs (AMTDT 1 and 2, respectively) with culture
and staining techniques for the direct detection of M. tuberculosis in respiratory and nonrespiratory specimens.
Patients and clinical specimens.
From November 1996 to May
1997, we investigated 682 respiratory and nonrespiratory specimens
collected from 515 patients at the Hospital Universitario Germans Trias
i Pujol, Barcelona, Spain. Only clinical samples from patients
suspected of having pulmonary and/or extrapulmonary tuberculosis were
included in the study. Four hundred ten respiratory specimens (335 expectorated sputum specimens, 45 bronchial and tracheal aspirate
specimens, and 30 bronchoalveolar lavage specimens) and 272 nonrespiratory specimens comprising 73 urine specimens, 29 pleural
fluid specimens, 26 ascitic fluid specimens, 21 cerebrospinal fluid
(CSF) specimens, 14 articular fluid specimens, 4 pericardial fluid
specimens, 16 bone marrow aspirate specimens, 38 biopsy or lymph node
exudate specimens, 16 purulent exudate specimens, 12 tissue biopsy
specimens, and 23 gastric juice aspirate specimens were included in the
study. Once collected, the specimens were kept at 4°C prior to
processing. Gastric juice aspirates were immediately neutralized with
trisodium phosphate buffer after retrieval.
Decontamination procedures.
Biopsy specimens were sliced and
homogenized in a mortar with 2 ml of 0.9% NaCl under sterile
conditions before processing. Urine and other fluid samples were
previously centrifuged at 3,300 × g for 20 min. All
samples with the exception of bone marrow aspirates were digested and
decontaminated with sodium dodecyl (lauryl) sulfate (SDS)-NaOH as
described previously (29, 30, 32). Briefly, 2 to 3 ml of a
specimen was transferred to a 50-ml plastic centrifuge tube, and an
equal volume of SDS-NaOH digestant solution (1% NaOH, 3% SDS [Fluka
Chemical Company, Buchs, Switzerland]) was added; after being
vortexed, the samples were vigorously shaken for 30 min. To neutralize
the specimen a 1.43% H3PO4 solution (containing 0.006% bromocresol purple as a pH indicator) was added. After a centrifugation step (3,300 × g, 20 min), the
supernatant was removed, the pellet was suspended with 30 ml of sterile
distilled water and centrifuged again (3,300 × g, 20 min), and the supernatant was removed. Bone marrow aspirates were
received in Isolator tubes (Wampole Laboratories, Cranbury, N.J.), and
1 ml of sample was treated with 100 µl of 10% SDS. After being
vortexed for 10 min at room temperature, bone marrow aspirates were
washed with 30 ml of distilled water and centrifuged (3,300 × g, 20 min), and the supernatant was removed. If the sediment
still had hemorrhagic contents, the process was repeated. The cell
pellets from all pretreated specimens were finally resuspended in 2.2 ml of 0.067 M phosphate buffer (pH 6.8). For all specimens, half of the
sediment was stored at Microscopy.
Smears were screened by staining with
auramine-rhodamine fluorochrome. Positive slides were confirmed by the
Ziehl-Neelsen technique (6, 19).
Culture.
Equal aliquots (approximately 250 µl) of the
processed sediment were inoculated onto two solid slants,
Löwenstein-Jensen and Coletsos (an egg-based medium containing
pyruvate, salts solution, asparagine, glutamate, glycerin, and
malachite green; with this medium the detection times for M. bovis and dysgonic strains of M. tuberculosis are
faster [8]) slants, and the slants were incubated at
37°C for 8 weeks in a humidified atmosphere. In addition, 500 µl of
the sediment was inoculated into BACTEC 12B medium (Becton-Dickinson Diagnostic Instrument Systems, Sparks, Md.) supplemented with 0.1 ml of
a mixture of antimicrobial agents (polymyxin B, azlocillin, nalidixic
acid, trimethoprim, and amphotericin B) and incubated at 37°C for up
to 8 weeks. Solid media were read weekly, and BACTEC cultures were read
twice weekly for the first 2 weeks and once weekly thereafter. A growth
index of >100 was considered positive for BACTEC cultures, and smears
for Ziehl-Neelsen staining and culture on Löwenstein-Jensen and
Coletsos media were prepared to detect acid-fast bacilli (AFB).
Identification of mycobacteria.
Routine biochemical methods
(17), gas-liquid chromatography (22), and the
Accuprobe culture confirmation tests (Gen-Probe Inc., San Diego,
Calif.) (16) were used for the identification of isolates.
AMTDTs.
The AMTDT uses an isothermal enzymatic amplification
system of target rRNA via DNA intermediates. Detection of amplicons is achieved by using an acridinium ester-labeled DNA probe. The tests were
performed according to the instructions on the package insert. The
AMTDT protocols consisted of the following steps. For lysis, 50 and 450 µl of the pretreated specimens were used in the initial and new
versions, respectively, and were added to 200 and 50 µl of specimen
dilution buffer, respectively, in a lysing tube, and the mixtures were
sonicated for 15 min in a water bath sonicator (Branson 1200; Branson
Ultrasonics Corporation, Danbury, Conn.) at room temperature. For
amplification, 25 and 50 µl of reconstituted amplification reagent
were used for AMTDT 1 and AMTDT 2, respectively. After the reaction,
the tubes were covered with 200 µl of mineral oil. Fifty and 25 µl
of lysate for AMTDT 1 and AMTDT 2, respectively, was transferred to the
amplification tubes, and the tubes were incubated at 95°C for 15 min
and then cooled at 42°C for 5 min. An enzyme reagent mixture (25 µl
for both tests) was added, and the mixture was incubated at 42°C for
2 h for AMTDT 1 and 45 min for AMTDT 2. To terminate amplification
(AMTDT 1 only), 20 µl of the termination reagent was added to each
tube, and the mixtures were kept at 42°C for another 10 min. For
detection by both tests, the reconstituted acridinium-labeled probe
(100 µl) was added to each tube, and the tubes were incubated at
60°C for 15 min, and then the selection reagent (300 µl) was added
and the mixtures were reincubated at 60°C for 10 min. All
temperature-controlled incubation steps were carried out in heating
blocks. All runs included AMTDT amplification-positive and -negative
controls and hybridization-positive and -negative controls. Prior to
being read in a luminometer (LEADER 50; Gen-Probe), the tubes were
cooled at room temperature for 5 to 10 min. The cutoff value was set at
30,000 relative light units (RLUs). Samples with values of >30,000
RLUs were considered positive; samples with values of <30,000 RLUs
were considered negative. An RLU ratio of sample RLUs/cutoff RLUs of
Evaluation of inhibition of AMTDTs.
All available specimens
that were positive for growth of M. tuberculosis but
negative by the AMTDTs and a group of randomly selected AFB
culture-positive and -negative specimens were analyzed for inhibition
of the AMTDTs. This was achieved by performing a second analysis by the
AMTDTs but with the addition of known amounts of RNA. The duplicate
vial contained 5 µl (i.e., 1/10) of the amount of the
amplification-positive control provided by the manufacturer and 45 µl
of lysate specimen for AMTDT 1 and 50 µl of the
amplification-positive control with 450 µl of lysate specimen for
AMTDT 2.
Clinical data for the patients.
For those specimens for
which the results of the culture and the amplification techniques were
discrepant, clinical data and other microbiological results for the
patient were analyzed. Clinical assessment included the patient's
history, signs, symptoms, chest X-ray results, and laboratory results;
cytological and histological results for the specimens; result of the
tuberculin skin test; and a history of the drugs that had been
administered. Moreover, all specimens with discrepant results were
retested with new aliquots of the same pretreated specimens.
Statistical analysis.
The sensitivities, specificities, and
positive predictive values (PPVs), and negative predictive values
(NPVs) of the amplification techniques were calculated by contrasting
the results with the culture results and the patient's clinical data.
Statistical comparisons were calculated by using the chi-square test; a
P value of <0.05 was considered significant.
The initial and new versions of AMTDT were evaluated for their
abilities to detect M. tuberculosis complex in 410 respiratory specimens from 275 patients and 272 nonrespiratory
specimens from 240 patients. These patients were suspected of having
pulmonary and/or extrapulmonary mycobacterial infections. The clinical
performance of the amplification assays was determined by comparison of
the results with those of standard culture and staining techniques. The
results for respiratory and nonrespiratory specimens were analyzed
separately.
Respiratory specimens.
Of the 410 respiratory specimens
examined, 95 were culture positive for M. tuberculosis.
Twenty-six specimens (19 specimens were smear positive) were culture
positive for nontuberculous mycobacteria (NTM). The species of NTM
identified from these specimens were M. avium complex
(n = 13), M. kansasii (n = 9), M. genavense (n = 3), and M. gordonae (n = 1). Two hundred eighty-nine
specimens (all smear negative) were culture negative.
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Comparative Evaluation of Initial and New Versions of the
Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test for Direct
Detection of Mycobacterium tuberculosis in Respiratory
and Nonrespiratory Specimens
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
80°C for the amplification techniques, and
the other half was used for acid-fast staining and culture.
1.0 was considered a positive result, as recommended by the
manufacturer.
![]()
RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
TABLE 1.
Detection of M. tuberculosis complex in
respiratory specimens by initial and new versions of AMTDT
TABLE 2.
Comparison of confirmed results for respiratory specimens
by AMTDT 1 and AMTDT 2
Nonrespiratory specimens. Of the 272 specimens examined, 68 were culture positive for M. tuberculosis. Of these, 21 (30.9%) specimens were smear positive and 47 (69.1%) specimens were smear negative. Nine specimens (three specimens were smear positive) were culture positive for NTM; the species of NTM identified from these specimens were M. avium complex (n = 3), M. kansasii (n = 5), and M. gordonae (n = 1). One hundred ninety-five specimens (all smear negative) were culture negative (Table 3).
|
|
|
Amplification inhibition. We also examined 150 specimens for the presence of inhibitors. None of the 24 specimens (13 respiratory and 11 nonrespiratory specimens) with AMTDT 1-negative results and culture-positive results for M. tuberculosis showed substances inhibitory to the amplification reaction. Of the 14 specimens (5 respiratory and 9 nonrespiratory specimens) with AMTDT 2-negative results and culture-positive results for M. tuberculosis, 5 specimens (1 respiratory and 4 nonrespiratory specimens) contained substances inhibitory to the amplification reaction. Among the randomly selected group of specimens, none of the 125 clinical specimens of respiratory and nonrespiratory origin contained inhibitors.
| |
DISCUSSION |
|---|
|
|
|---|
One feature of the mycobacteria belonging to the M. tuberculosis complex which delays detection in cultures is the slow division time, about 20 h under the best culture conditions (32). When a clinical specimen is smear negative, it takes several weeks for the culture to become positive, even when the most appropriate culture techniques are used (1, 9, 17). To provide physicians with accurate and rapid bacteriological results, it is necessary to shorten the delay in reporting the presence of M. tuberculosis in clinical specimens. The most promising diagnostic modality for addressing this problem is PCR. Several research groups have described different PCR systems and/or have performed clinical studies based on PCR (4, 5, 7, 11, 12, 14, 20). The investigators reported widely different results with respect to specificity and sensitivity. One reason for this may be methodological differences concerning sample preparation; others may be the volume of sample used for DNA extraction and the design of the amplification and detection procedures. The main problem with DNA amplification methods is the low sensitivity found with smear-negative samples.
In the past few years, Gen-Probe has provided the ready-to-use AMTDT, a kit for the direct detection of M. tuberculosis in clinical specimens. This system uses the transcription-mediated amplification method to amplify target rRNA via DNA intermediates, followed by chemiluminescence detection of the amplicon with an acridinium ester-labeled DNA probe. The analytical sensitivity of the test is one cell, and the assay only detects members of the M. tuberculosis complex (18). AMTDT detects rRNA, which is present at a level of approximately 2,000 copies per cell (18). This advantage enhances the sensitivity of the test compared with those of tests which detect the target sequences present in only a single or a very low copy number (28).
This initial version of AMTDT (AMTDT 1) has been sufficiently evaluated against culture methods and AFB smears with respiratory specimens (2, 18, 21, 26, 31). For more than 5,000 respiratory specimens, AMTDT 1 yielded overall sensitivities of between 82 and 97% and overall specificities of between 97 and 100%. Also, the sensitivity and specificity results for AMTDT 1 with nonrespiratory specimens were shown to be as high as those reported by other investigators with respiratory specimens (13, 15, 27).
Recently, Gen-Probe has developed the second version of AMTDT (AMTDT 2), which has an enhanced protocol. The enhancements include (i) the use of a larger quantity of pretreated specimen (450 µl), (ii) a reduction in the incubation time of the amplification reaction (60 to 30 min), and (iii) elimination of the termination reaction.
The purpose of the present study was to compare AMTDT 1 with AMTDT 2 and culture and staining techniques for the direct detection of M. tuberculosis in respiratory and nonrespiratory specimens.
The overall results of AMTDT 1 and AMTDT 2 were concordant for 97.3 and 96.3% of the respiratory and nonrespiratory specimens, respectively.
We obtained with respiratory specimens 13 false-negative results by AMTDT 1 and 5 false-negative results by AMTDT 2. With nonrespiratory specimens there were 11 false-negative results by AMTDT 1 and 9 false-negative results by AMTDT 2. These specimens exhibited positive radiometric culture results within a period of 20 to 45 days and showed 1 to 10 colonies on solid media. With respiratory and nonrespiratory specimens, none of the specimens with false-negative results by AMTDT 1 were shown to contain substances inhibitory to the amplification reaction. With regard to the five respiratory specimens with false-negative results by AMTDT 2, only one specimen contained inhibitors. Four of the nine nonrespiratory specimens with false-negative results by AMTDT 2 were found to contain substances inhibitory to the amplification reaction. In conclusion, the 35.7% (five samples) of the 14 samples with false-negative results showed evidence of containing substances inhibitory to the amplification for AMTDT 2. Therefore, we believe that in the present study the false-negative results obtained by AMTDT 1 were not due to sample inhibition but were due to either a sampling error because of a low number of microorganisms or a nonuniform distribution of these microorganisms in the clinical samples. In contrast, the false-negative results obtained by AMTDT 2 were due both to sample inhibition and to the presence of a low number of microorganisms in the clinical sample. For that reason, the AMTDT 2 kit should include internal controls in order to assess the efficacy of each amplification reaction and to ensure that the sample is free of interfering substances. The use of internal controls will identify those samples that are inappropriate for amplification or that require further manipulation to remove inhibitory substances, and the use of internal controls will ultimately increase confidence in the reliability of negative results.
In conclusion, for respiratory specimens, the sensitivity and specificity of AMTDT 1 were 83 and 100%, respectively, and those of AMTDT 2 were 94.7 and 100%, respectively. For nonrespiratory specimens, the sensitivity and specificity of AMTDT 1 were 83 and 100%, respectively, and those of AMTDT 2 were 86.8 and 100%, respectively. For respiratory specimens only were statistically significant differences in the sensitivities found between AMTDT 1 and AMTDT 2 (P = 0.047).
In tests with respiratory and nonrespiratory specimens, our study population had rates of positivity for M. tuberculosis of 23.2 and 25%, respectively. For 48 (50.5%) respiratory specimens with smear-positive results and 47 (49.5%) specimens with smear-negative results, the sensitivities were 100 and 72.3%, respectively, for AMTDT 1 and 100 and 83%, respectively, for AMTDT 2. For 21 (30.9%) nonrespiratory specimens with smear-positive results and 47 (69.1%) specimens with smear-negative results, the sensitivities were 100 and 76.6%, respectively, for AMTDT 1 and 100 and 88.9%, respectively, for AMTDT 2.
Similar results were obtained for AMTDT 1 in a comparative evaluation with the Roche Amplicor MTB Test, carried out with 327 respiratory specimens from 236 patients (28). With a prevalence of 15% and a staining sensitivity of 70%, the sensitivities for smear-positive and smear-negative specimens were 100 and 85.7%, respectively, for AMTDT 1 and 96.7 and 50%, respectively, for the Amplicor MTB Test.
Vuorinen et al. (31) evaluated AMTDT 1 and the Amplicor MTB Test with 256 respiratory specimens from 243 patients and found a rate of positivity of 12.7% and a staining sensitivity of 76%. Lower sensitivities were obtained for smear-negative specimens by AMTDT 1 (42.9%) and the Amplicor MTB Test (28.6%).
In a further study (27) AMTDT 1 was evaluated with 1,117 respiratory specimens and 322 nonrespiratory specimens, with a rate of positivity of 12% and a staining sensitivity of 40%. For respiratory specimens, the sensitivities obtained with smear-positive and smear-negative specimens were 98.5 and 81%, respectively, and those obtained with nonrespiratory specimens were 99.3 and 90.5%, respectively. These results are in good accordance with the results obtained in our comparative study of AMTDT 1 and AMTDT 2.
With respect to specimens smear positive and culture positive for M. tuberculosis, the sensitivity of both AMTDTs was 100%. It is very important to indicate that AMTDT 2 does not appear to be susceptible to inhibition by substances present in this class of specimens. Therefore, smear-positive and AMTDT-negative results can suggest the detection of a nontuberculous mycobacterium.
In conclusion, (i) AMTDT 1 and AMTDT 2 are highly sensitive and specific techniques for the rapid detection of M. tuberculosis in all types of clinical samples. (ii) Although AMTDT 2 is more susceptible to inhibitors than AMTDT 1, the sensitivity of AMTDT 2 is higher than that of AMTDT 1 with smear-negative specimens. (iii) In addition, the turnaround time of AMTDT 2 is shorter (3.5 h) than that of AMTDT 1 (5 h). (iv) Finally, AMTDT 2 should incorporate an internal control for the evaluation of amplification inhibitors in the clinical samples.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Servicio de Microbiología, Hospital Universitario Germans Trias i Pujol, Carretera del Canyet s/n, 08916 Badalona, Spain. Phone: 34-3-4651200, ext. 393. Fax: 34-3-4657019. E-mail: VAUSINA{at}NS.HUGTIP.SCS.ES.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Abe, C.,
S. Hosojima,
Y. Fucosava,
Y. Kazumi,
M. Takahashi,
K. Hirao, and T. Mori.
1992.
Comparison of MB-Check, BACTEC, and egg-based media for recovery of mycobacteria.
J. Clin. Microbiol.
30:878-881 |
| 2. |
Abe, C.,
K. Hirano,
M. Wada,
Y. Kazumi,
M. Takahashi,
Y. Fukasawa,
T. Yoshimura,
C. Miyagi, and S. Goto.
1993.
Detection of Mycobacterium tuberculosis in clinical specimens by polymerase chain reaction and Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test.
J. Clin. Microbiol.
31:3270-3274 |
| 3. |
Bodmer, T.,
A. Gurtner,
K. Schopfer, and L. Maner.
1994.
Screening of respiratory tract specimens for the presence of Mycobacterium tuberculosis by using the Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test.
J. Clin. Microbiol.
32:1483-1487 |
| 4. | Brisson-Noël, A., B. Gicquel, D. Lecossier, V. Lévy-Frébault, X. Nassif, and A. J. Hance. 1989. Rapid diagnosis of tuberculosis by amplification of mycobacterial DNA in clinical samples. Lancet ii:1069-1071. |
| 5. | Brisson-Noël, A., C. Aznar, C. Chureau, S. Nguyen, C. Pierre, M. Bartoli, R. Bonete, G. Pialoux, B. Gicquel, and G. Garrigue. 1991. Diagnosis of tuberculosis by amplification of mycobacterial DNA in clinical practical evaluation. Lancet 338:364-366[Medline]. |
| 6. | Chain, K. 1995. Clinical microscopy, p. 33-51. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C. |
| 7. |
Clarridge, J. E., III,
R. M. Shawar,
T. M. Shinnick, and B. B. Plikaytis.
1993.
Large-scale use of polymerase chain reaction for detection of Mycobacterium tuberculosis in a routine mycobacteriology laboratory.
J. Clin. Microbiol.
31:2049-2056 |
| 8. | Coletsos, P. J. 1960. Milieu et modalités de culture adaptés à la réanimación et à la multiplication in vitro de Mycobacterium tuberculosis de vitalité réduite de viabilité éphémère ou en état de quiescence. Ann. Inst. Pasteur 99:475-495[Medline]. |
| 9. | Daniel, T. M. 1990. The rapid diagnosis of tuberculosis: a selective review. J. Lab. Clin. Med. 116:277-282[Medline]. |
| 10. |
Del Portillo, P.,
L. A. Murillo, and M. E. Patarroyo.
1991.
Amplification of a species-specific DNA fragment of Mycobacterium tuberculosis and its possible use in diagnosis.
J. Clin. Microbiol.
29:2163-2168 |
| 11. |
De Wit, D.,
L. Steyn,
S. Shoemaker, and M. Soguin.
1990.
Direct detection of Mycobacterium tuberculosis in clinical specimens by DNA amplification.
J. Clin. Microbiol.
28:2437-2441 |
| 12. |
De Wit, D.,
M. Wooton,
B. Allan, and L. Steyn.
1993.
Simple method for production of internal control DNA for Mycobacterium tuberculosis polymerase chain reaction assays.
J. Clin. Microbiol.
31:2204-2207 |
| 13. | Ehlers, S., R. Ignatius, T. Regnath, and H. Hahn. 1996. Diagnosis of extrapulmonary tuberculosis by Gen-Probe Amplified Mycobacterium tuberculosis Direct Test. J. Clin. Microbiol. 34:2275-2279[Abstract]. |
| 14. |
Folgueira, L.,
R. Delgado,
E. Palenque, and A. R. Noriega.
1993.
Detection of Mycobacterium tuberculosis DNA in clinical samples by using a simple lysis method and polymerase chain reaction.
J. Clin. Microbiol.
31:1019-1021 |
| 15. | Gamboa, F., J. M. Manterola, B. Viñado, L. Matas, M. Giménez, J. Lonca, J. R. Manzano, C. Rodrigo, P. J. Cardona, E. Padilla, J. Dominguez, and V. Ausina. 1997. Direct detection of Mycobacterium tuberculosis complex in nonrespiratory specimens by Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test. J. Clin. Microbiol. 35:307-310[Abstract]. |
| 16. |
Goto, M.,
S. Oka,
K. Okuzumi,
S. Kimura, and K. Shimada.
1991.
Evaluation of acridinium-ester-labeled DNA probes for identification of Mycobacterium tuberculosis and Mycobacterium avium-Mycobacterium intracellulare complex in culture.
J. Clin. Microbiol.
29:2473-2476 |
| 17. | Heifets, L. B., and R. C. Good. 1994. Current laboratory methods for the diagnosis of tuberculosis, p. 85-110. In B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology, Washington, D.C. |
| 18. |
Jonas, V.,
M. J. Alden,
J. I. Curry,
K. Kamisango,
C. A. Knott,
R. Lankford,
J. M. Wolfe, and D. F. Moore.
1993.
Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by amplification of RNA.
J. Clin. Microbiol.
31:2410-2416 |
| 19. | Kent, P. T., and G. P. Kubica. 1985. Public health mycobacteriology. A guide for the level III laboratory. Public Health Service, U.S. Department of Health and Human Services, Atlanta, Ga. |
| 20. |
Kox, L. F. F.,
D. Rhienthong,
A. Medo Miranda,
N. Udomsantisuk,
K. Ellis,
J. van Leeuwen,
S. van Heusden,
S. Kuijper, and A. H. J. Kolk.
1994.
A more reliable PCR for detection of Mycobacterium tuberculosis in clinical samples.
J. Clin. Microbiol.
32:672-678 |
| 21. | La Rocco, M. T., A. Wagner, H. Ocera, and E. Macias. 1994. Evaluation of a commercial rRNA amplification assay for direct detection of Mycobacterium tuberculosis. Eur. J. Clin. Microbiol. Infect. Dis. 33:726-731. |
| 22. |
Luquin, M.,
V. Ausina,
F. López-Calahorra,
F. Belda,
M. García-Barceló,
C. Celma, and G. Prats.
1991.
Evaluation of practical chromatographic procedures for identification of clinical isolates of mycobacteria.
J. Clin. Microbiol.
29:120-130 |
| 23. |
Noordhoek, G. T.,
A. H. J. Kolk,
G. Bjune,
D. Catty,
J. W. Dale,
P. E. M. Fine,
P. Godfrey-Faussett,
S.-N. Cho,
T. Shinnick,
S. B. Svenson,
S. Wilson, and J. D. A. Van Embden.
1994.
Sensitivity and specificity of PCR for detection of Mycobacterium tuberculosis: a blind comparison study among seven laboratories.
J. Clin. Microbiol.
32:277-284 |
| 24. | Noordhoek, G. T., J. D. A. Embden, and A. H. J. Kolk. 1996. Reliability of nucleic acid amplification for detection of Mycobacterium tuberculosis: an international collaborative quality control study among 30 laboratories. J. Clin. Microbiol. 34:522-525. |
| 25. | Pfyffer, G. E. 1994. Amplification techniques: hope or illusion in the direct detection of tuberculosis. Med. Microbiol. Lett. 3:335-347. |
| 26. |
Pfyffer, G. E.,
P. Kissling,
R. Wirth, and R. Weber.
1994.
Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by a target-amplified test system.
J. Clin. Microbiol.
32:918-923 |
| 27. | Pfyffer, G. E., P. Kissling, E. M. I. Jahn, H.-M. Welscher, M. Salfinger, and R. Weber. 1996. Diagnostic performance of amplified Mycobacterium tuberculosis direct test with cerebrospinal fluid, other nonrespiratory, and respiratory specimens. J. Clin. Microbiol. 34:834-841[Abstract]. |
| 28. | Piersimoni, C., A. Callegaro, D. Nista, S. Bornigia, F. De Conti, G. Santini, and G. De Sio. 1997. Comparative evaluation of two commercial amplification assays for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J. Clin. Microbiol. 35:193-196[Abstract]. |
| 29. | Salfinger, M., and F. M. Kafader. 1987. Comparison of two pretreatment methods for the detection of mycobacteria of BACTEC and Löwenstein-Jensen slants. J. Microbiol. Methods 6:315-321. |
| 30. |
Sjobring, U.,
M. Mecklenburg,
A. Bergard Andersen, and H. Miürner.
1990.
Polymerase chain reaction for detection of Mycobacterium tuberculosis.
J. Clin. Microbiol.
28:2200-2204 |
| 31. | Vuorinen, P., A. Miettinen, R. Vuento, and O. Hällström. 1995. Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test and Roche Amplicor Mycobacterium Tuberculosis Test. J. Clin. Microbiol. 33:1856-1859[Abstract]. |
| 32. | Wayne, L. G. 1994. Cultivation of Mycobacterium tuberculosis for research purposes, p. 73-83. In B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology, Washington, D.C. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|